What are you searching for?

Sign in
Breaking News

Piramal Pharma Solutions Launches In-Vitro Biology Capabilities

Expansion couples new biology services with existing chemistry capabilities.

By: Kristin Brooks

Managing Editor, Contract Pharma

Piramal Pharma Ltd.’s Pharma Solutions (PPS) CDMO business, launched a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. The expansion adds significant primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.

The company can now provide clients with an integrated set of discovery capabilities and leverage a wide range of in-vitro screening technology tools to support its broad portfolio of research services. The goal is to generate data that provides a superior data package for clients and enhance the company’s value as an outsourcing partner. The integration of chemistry and biology services under one roof aims to add high efficiency to the discovery process. 
 
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process.”
 
The new high-throughput screening format enables PPS to evaluate and screen large collections using various assay platform technologies including, TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) / HTRF (Homogeneous Time-Resolved Fluorescence), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high-content imaging. These platforms will be applicable to a variety of targets including but not limited to G-Protein-Coupled Receptors (GPCRs) and kinases.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics